Market Cap
$31.7M
QNCX
Quince Therapeutics, Inc.
$30.20 ▼ -1.56%
Prev close $30.68Market cap$31.7M
ConsensusBuy
12-mo target$75.43 (+149.8%)
▲ Bullish
Analyst conviction 7/10
High Impact Filing (8/10) Biotech & Drug Discovery
Snapshot
The big-picture read on QNCX right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Analyst Consensus
Buy (69%)
Inst. Holders
19 funds
Inst. Value
$19.8M
Inst. Activity
1 buys / 0 sells
Social Sentiment
65° Warm
SEC Reports
9
Price chart 30d -6.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 9, 2026 listing_status
Sep 4, 2026 SEC Listing Status: QNCX — Deficient (was Normal)
Quince Therapeutics, Inc. - Common Stock | Nasdaq Financial Status Indicator N → D
Quince Therapeutics received a Nasdaq delisting notice on August 31, 2026, for failing the minimum stockholders' equity
8-K — Impact 8/10
Quince Therapeutics' S-3 shelf registration (File No. 333-297903) became effective on August 24, 2026. The shelf registe
EFFECT — Impact 5/10
Quince Therapeutics reported Q2 2026 results reflecting the transformational acquisition of Orphai Therapeutics and a co
8-K — Impact 5/10
Jun 30, 2026 Inst.
BALYASNY ASSET MANAGEMENT L.P. — NEW
69,967 shares ($12.6M)
Jun 11, 2026 Insider
Lamond David was granted 2,700 shares
Director
Jun 11, 2026 Insider
Senner Christopher J. was granted 2,700 shares
Director
May 18, 2026 Insider
Roberts Brigette was granted 34,675 shares
Chief Corp. Affairs Officer
Analyst ratings buy % -25.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
69% rate it Buy or better · 13 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 24, 2026 | Rodman & Renshaw | INITIATE | Buy | 39% |
| Sep 22, 2026 | Citizens | UPGRADE | Market Outperform | 38% |
| Aug 18, 2026 | Cantor Fitzgerald | REITERATE | Overweight | 49% |
| Jul 29, 2026 | Oppenheimer | INITIATE | Outperform | 52% |
| Jun 24, 2026 | Leerink Partners | INITIATE | Outperform | 49% |
| Jun 23, 2026 | Cantor Fitzgerald | INITIATE | Overweight | 49% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 5 | 4 | 0 | 0 | 69% | |
| Aug 1, 2026 | 4 | 5 | 4 | 0 | 0 | 69% | |
| Jul 1, 2026 | 3 | 5 | 4 | 0 | 0 | 67% | |
| Jun 1, 2026 | 0 | 0 | 5 | 1 | 2 | 0% | |
| May 1, 2026 | 0 | 0 | 5 | 2 | 2 | 0% | |
| Apr 1, 2026 | 0 | 0 | 5 | 2 | 2 | 0% | |
| Mar 1, 2026 | 0 | 0 | 5 | 2 | 2 | 0% | |
| Feb 1, 2026 | 1 | 0 | 6 | 2 | 2 | 9% |
Price targets
Where 7 covering analysts think QNCX trades over the next 12 months.
$75.43 +149.8% upside Strong Buy
Current$30.20 Low$65.00 Median$70.00 High$98.00 7 analysts
$65.00$98.00
Analyst rating Strong Buy· 1.4/5 as of Oct 2, 2026
Social media sentiment mood +7.1%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
65°
Warm
BearishNeutralBullish
Recent posts
People declare reverse-split arbitrage dead every slow month
▲ 1 · 💬 1· ⚡ 0.5
QNCX: Announces 10 to 1 reverse split starting on monday and also skyrockets can you make it make sense?
▲ 1 · 💬 1· ⚡ 0.5
08 April 2026 , Top Pre-Market Gainers (Small-Cap Focus)
▲ 1 · 💬 0· ⚡ 0.5
08 April 2026 Top Pre-Market Gainers (Small-Cap Focus)
▲ 1 · 💬 0· ⚡ 0.5
24 MARCH 2026 , WHAT ARE THE BIGGEST WINNERS IN PRE-MARKET AND WHY ?
▲ 1 · 💬 1· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 1 bullish, 2 bearish, 1 mixed, 5 neutral · avg impact 4.6/10.
BEARISH8-K8/10
Quince Therapeutics received a Nasdaq delisting notice on August 31, 2026, for failing the minimum s
Sep 4, 2026
BEARISHEFFECT5/10
Quince Therapeutics' S-3 shelf registration (File No. 333-297903) became effective on August 24, 202
Aug 25, 2026
NEUTRAL8-K5/10
Quince Therapeutics reported Q2 2026 results reflecting the transformational acquisition of Orphai T
Aug 14, 2026
BULLISHPRESS-RELEASE6/10
Quince Therapeutics reported Q2 2026 results highlighting a strengthened balance sheet with $116M ca
Aug 14, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 9, 2026
listing_status
Listing Status: QNCX — Deficient (was Normal)
Quince Therapeutics, Inc. - Common Stock | Nasdaq Financial Status Indicator N → D
Sep 3, 2026
other
Quince Therapeutics to Participate in September 2026 Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company f
Aug 14, 2026
earnings
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved p
Aug 10, 2026
earnings_calendar
QNCX Q2 2026 Earnings Scheduled — 2026-08-10
Jun 30, 2026
other
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company fo
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.20 | $-1.40–$-0.83 | 97.6% | -9.1% | — | $0.0B | 3 |
| Next Q | $-1.11 | $-1.60–$-0.71 | 99.3% | -28.3% | — | $0.0B | 3 |
| Current FY | $-3.65 | $-8.00–$-0.96 | 98.9% | +0.0% | — | $0.0B | 3 |
| Next FY | $-4.68 | $-6.60–$-3.49 | -28.2% | +0.0% | — | $0.0B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.200 | — |
| 7d ago | $-1.200 | — |
| 30d ago | $-1.100 | -0.100 |
| 60d ago | $-1.403 | +0.203 |
| 90d ago | $-8.800 | +7.600 |
Institutional ownership
Which big funds own QNCX (from quarterly 13F filings) and who is adding or trimming.
19 institutional holders with $19.8M total value (468,229 shares) as of 2026-Q2. Top holders: ROYAL, BALYASNY, TUDOR. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| ROYAL BANK OF CANADA | 1 | $0.00 | 0.0% | — |
| BALYASNY ASSET MANAGEMENT L.P. | 69,967 | $12.6M | 63.4% | NEW |
| TUDOR INVESTMENT CORP ET AL | 117,800 | $2.1M | 10.8% | — |
| TUDOR INVESTMENT CORP ET AL | 115,800 | $2.1M | 10.6% | — |
| MILLENNIUM MANAGEMENT LLC | 70,779 | $1.3M | 6.5% | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 55,000 | $1.0M | 5.1% | — |
| JANE STREET GROUP, LLC | 12,642 | $230.0K | 1.2% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 12,044 | $219.1K | 1.1% | — |
| UBS Group AG | 4,730 | $86.0K | 0.4% | — |
| MORGAN STANLEY | 4,084 | $74.3K | 0.4% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BALYASNY ASSET MANAGEMENT L.P. | NEW | — | 69,967 | — | $12.6M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
3 insiders, 10 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | Lamond David | Director | AWARD | 2,700 | — | — |
| Jun 11, 2026 | Senner Christopher J. | Director | AWARD | 2,700 | — | — |
| May 18, 2026 | Roberts Brigette | Chief Corp. Affairs Officer | AWARD | 34,675 | — | — |
| May 18, 2026 | Roberts Brigette | Chief Corp. Affairs Officer | AWARD | 228,855 | — | — |
| May 18, 2026 | Roberts Brigette | Chief Corp. Affairs Officer | AWARD | 124,830 | — | — |
| May 18, 2026 | Roberts Brigette | Chief Corp. Affairs Officer | AWARD | 69,350 | — | — |
| May 18, 2026 | Roberts Brigette | Chief Corp. Affairs Officer | AWARD | 362,092 | — | — |
| May 18, 2026 | Roberts Brigette | Chief Corp. Affairs Officer | AWARD | 133,615 | — | — |
| May 18, 2026 | Roberts Brigette | Chief Corp. Affairs Officer | AWARD | 2,070,107 | — | — |
| May 18, 2026 | Roberts Brigette | Chief Corp. Affairs Officer | AWARD | 6,837,319 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for QNCX.
Shares short
50,273
Settlement Sep 15, 2026
Change vs prior
-11.8%
Semi-monthly cycle
Days to cover
3.0
At avg daily volume
Of shares outstanding
≈4.9%
Estimate — not % of float
All QNCX filing & press-release reports (9)
- 8-K reportSep 4, 2026
- EFFECT reportAug 25, 2026
- 8-K reportAug 14, 2026
- PRESS-RELEASE reportAug 14, 2026
- S-3/A reportAug 5, 2026
- 3 reportJun 11, 2026
- 8-K reportMay 18, 2026
- DEFA14A reportApr 27, 2026
- 8-K reportApr 9, 2026